Celator joins leukemia society for phase II trial of CPX-351

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

Celator Pharmaceuticals and the Leukemia & Lymphoma Society have partnered for the phase II development of CPX-351 (cytarabine:daunorubicin), a liposome injection for treatment of adults with acute myeloid leukemia.

Celator Pharmaceuticals and the Leukemia & Lymphoma Society have partnered for the phase II development of CPX-351 (cytarabine:daunorubicin), a liposome injection for treatment of adults with acute myeloid leukemia.

Through the partnership, the society will provide $3.7 million to support the multicenter, randomized, open-label trial of CPX-351 compared with intensive salvage therapy in adult patients (≤ 60 years of age) with AML in first relapse. Celator expects to start patient enrollment in this study in the first quarter of 2009 in the U.S. and Canada. CPX-351 has also been granted orphan drug status by the FDA for the treatment of AML.

The collaboration is part of the society’s Therapy Acceleration Program, which supports private sector and academic-based projects that advance investigational therapies.

Articles in this issue
Consortium advances multidisciplinary program for colon cancer
Celator joins leukemia society for phase II trial of CPX-351
Genzyme nabs FDA approval for stem cell mobilizing agent
FDA launches pilot safety program for foreign drugs
Radiation oncology society adopts new moniker
Varian places RT units; offers storage system
Improvements in Pap screenings proposed
New outlook for neuroendocrine cancer
Elderly multiple myeloma patients remain responsive to novel therapy teamed with conventional treatment
Mismatched cord blood stem cells meet need for urgent Rx in acute leukemia
Risk of transplantrelated mortality doesn’t increase with cord blood
NSABP B-30: Amenorrhea relates to survival
Easy methods curtail toxins in food linked to cancer in Africa
Growth of Medicare HMOs could impact clinical trials
Trastuzumab in the adjuvant setting: Is concurrent treatment better than sequential?
Recent Videos
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Related Content
Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.

Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population

Russ Conroy
November 23rd 2025
Article

Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Radiation ± Chemotherapy Shows Worse Short-Term QOL in Cervical Cancer

Russ Conroy
November 22nd 2025
Article

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.

Fertility-Sparing Surgery May Be Safe Despite Recurrence in Cervical Cancer

Tim Cortese
November 21st 2025
Article

Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.

Pharmacokinetic data from the phase 1/2 GO29781 study support the European approval of subcutaneous mosunetuzumab in this follicular lymphoma population.

Subcutaneous Mosunetuzumab Earns EU Approval in R/R Follicular Lymphoma

Russ Conroy
November 21st 2025
Article

Pharmacokinetic data from the phase 1/2 GO29781 study support the European approval of subcutaneous mosunetuzumab in this follicular lymphoma population.